A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Autor: Le X; UT MD Anderson Cancer Center, Houston, TX., Patel JD; Northwestern University, Chicago, IL., Shum E; New York University Cancer Center, New York, NY., Baik C; University of Washington, Seattle, WA., Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR., Shu CA; Columbia University Irving Medical Center, New York, NY., Kim C; Georgetown University, Washington, DC., Fidler MJ; Rush University, Chicago, IL., Hall R; Virginia University, Charlottesville, VA., Elamin YY; UT MD Anderson Cancer Center, Houston, TX., Tu J; UT MD Anderson Cancer Center, Houston, TX., Blumenschein G; UT MD Anderson Cancer Center, Houston, TX., Zhang J; UT MD Anderson Cancer Center, Houston, TX., Gibbons D; UT MD Anderson Cancer Center, Houston, TX., Gay C; UT MD Anderson Cancer Center, Houston, TX., Mohindra NA; Northwestern University, Chicago, IL., Chae Y; Northwestern University, Chicago, IL., Boumber Y; Northwestern University, Chicago, IL., Sabari J; New York University Cancer Center, New York, NY., Santana-Davila R; University of Washington, Seattle, WA., Rogosin S; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR., Herzberg B; Columbia University Irving Medical Center, New York, NY., Creelan B; Moffitt Cancer Center, Tampa, FL., Pellini B; Moffitt Cancer Center, Tampa, FL., Tanvetyanon T; Moffitt Cancer Center, Tampa, FL., Heeke S; UT MD Anderson Cancer Center, Houston, TX., Hernandez M; UT MD Anderson Cancer Center, Houston, TX., Gray JE; Moffitt Cancer Center, Tampa, FL., Saltos A; Moffitt Cancer Center, Tampa, FL., Heymach JV; UT MD Anderson Cancer Center, Houston, TX.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 08, pp. JCO2400533. Date of Electronic Publication: 2024 Oct 08.

Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.

Autor: Florez N; Harvard Medical School, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kiel L; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Meza K; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Wei Z; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Mazzola E; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Velazquez AI; UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Franco I; Harvard Medical School, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Brigham and Women's Hospital, Boston, Massachusetts, USA., Fidler MJ; Rush University Medical Center, Chicago, Illinois, USA., Elkins I; EGFR Resisters, Chicago, Illinois, USA., Feldman J; EGFR Resisters, Chicago, Illinois, USA., Seaborne L; University of Wisconsin, Madison, Wisconsin, USA., Heisler C; University of Wisconsin, Madison, Wisconsin, USA., King JC; GO2 for Lung Cancer, Washington, District of Columbia, USA., Moore A; LUNGevity Foundation for Lung Cancer, Bethesda, Maryland, USA., Wiens J; Merck Pharmaceuticals, Rahway, New Jersey, USA., Kushner D; University of Wisconsin, Madison, Wisconsin, USA.

Publikováno v: Cancer [Cancer] 2024 Feb 01; Vol. 130 (3), pp. 375-384. Date of Electronic Publication: 2023 Oct 16.

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.

Autor: John T; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. Electronic address: Tom.John@petermac.org., Grohé C; Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany., Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California., Shepherd FA; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada., de Marinis F; Thoracic Oncology Division, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy., Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi Ward, Yokohama, Japan., Wang Q; Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China., Su WC; Department of Oncology, National Cheng Kung University, Tainan, Taiwan., Choi JH; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea., Sriuranpong V; Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Melotti B; Division of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Fidler MJ; Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois., Chen J; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China., Albayaty M; Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom., Stachowiak M; Late Oncology Research & Development, AstraZeneca, Warsaw, Poland., Taggart S; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China., Tsuboi M; Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Herbst RS; Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut., Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Sep; Vol. 18 (9), pp. 1209-1221. Date of Electronic Publication: 2023 May 24.

Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.

Autor: King K; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, U.S.A.; Kevin_King@Rush.edu., Rauch R; Rush University Medical College, Rush University Medical Center, Chicago, IL, U.S.A., Roy S; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, U.S.A., Menyok O; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Tatebe K; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, U.S.A., Tajudeen B; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Papagiannopoulos P; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Batra PS; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Bhayani M; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Al-Khudari S; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Stenson K; Department of Otorhinolaryngology, Head and Neck Surgery, Rush University Medical Center, Chicago, IL, U.S.A., Jelinek MJ; Department of Medical Oncology, Rush University Medical Center, Chicago, IL, U.S.A., Fidler MJ; Department of Medical Oncology, Rush University Medical Center, Chicago, IL, U.S.A., Joshi N; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, U.S.A.

Publikováno v: Anticancer research [Anticancer Res] 2022 Nov; Vol. 42 (11), pp. 5449-5455.

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.

Autor: Bestvina CM; Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Whisenant JG; Vanderbilt University Medical Center, Nashville, Tennessee., Torri V; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy., Cortellini A; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Wakelee H; Stanford Cancer Institute, Stanford University, Stanford, California., Peters S; Lausanne University Hospital, Lausanne University, Lausanne, Switzerland., Roca E; Thoracic Oncology-Lung Unit, Ospedale Pederzoli, Peschiera dG, Verona, Italy., De Toma A; Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy., Hirsch FR; Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York., Mamdani H; Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Halmos B; Division of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York., Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico., Metivier AC; Department of Pneumology, Hopital Foch, Suresnes, France., Fidler MJ; Department of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, Illinois., Rogado J; Seccion de Oncologia Medica, Hospital Universitario Infanta Leonor, Madrid, Spain., Presley CJ; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Mascaux C; Service De Pneumologie, Hopitaux Universitaires De Strasbourg, Strasbourg, France.; Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), Inserm UMR_S 1113, IRFAC, ITI InnoVec, Universite De Strasbourg, Strasbourg, France., Genova C; UOC Clinica di Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy.; Dipartimento di Medicina Interna e Specialita Mediche (DIMI), Universita degli Studi di Genova, Genoa, Italy., Blaquier JB; Thoracic Oncology Section, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina., Addeo A; University Hospital of Geneva, Geneva, Switzerland., Finocchiaro G; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy., Khan H; The Warren Alpert Medical School of Brown University, Providence, Rhode Island., Mazieres J; Toulouse University Hospital, Université Paul Sabatier, Toulouse, France., Morgillo F; Department of Precision Medicine, Medical Oncology and Haematology, Universita degli studi della Campania 'L. Vanvitelli,' Naples, Italy., Bar J; Institute of Oncology, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel., Aujayeb A; Respiratory Department, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom., Mountzios G; Fourth Department of Medical Oncology and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece., Scotti V; Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy., Grosso F; Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Geraedts E; Groene Hart Ziekenhuis, Gouda, The Netherlands., Zhumagaliyeva AN; Semey Medical University, Center for Nuclear Medicine and Oncology of Semey, Semey, Kazakhstan., Horn L; Vanderbilt University Medical Center, Nashville, Tennessee., Garassino MC; Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Baena J; Hospital Universitario 12 de Octubre, Madrid, Spain.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2022 Aug; Vol. 3 (8), pp. 100335. Date of Electronic Publication: 2022 May 20.